Nathan Hambly

1.6k total citations
35 papers, 524 citations indexed

About

Nathan Hambly is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Nathan Hambly has authored 35 papers receiving a total of 524 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 18 papers in Physiology and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Nathan Hambly's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (25 papers), Sarcoidosis and Beryllium Toxicity Research (15 papers) and Pulmonary Hypertension Research and Treatments (8 papers). Nathan Hambly is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (25 papers), Sarcoidosis and Beryllium Toxicity Research (15 papers) and Pulmonary Hypertension Research and Treatments (8 papers). Nathan Hambly collaborates with scholars based in Canada, Australia and Saudi Arabia. Nathan Hambly's co-authors include Martin Kolb, Parameswaran Nair, Christopher J. Ryerson, Jolene H. Fisher, Kerri A. Johannson, Chiko Shimbori, Shane Shapera, Gerard Cox, Julie Morisset and H. Manganas and has published in prestigious journals such as Circulation, CHEST Journal and BMJ.

In The Last Decade

Nathan Hambly

32 papers receiving 515 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nathan Hambly Canada 14 412 200 48 44 39 35 524
Vladimír Koblížek Czechia 16 637 1.5× 332 1.7× 73 1.5× 57 1.3× 22 0.6× 62 862
Bridget F. Collins United States 12 525 1.3× 237 1.2× 165 3.4× 65 1.5× 37 0.9× 27 703
Rasmus Holmboe Dahl Denmark 11 169 0.4× 139 0.7× 47 1.0× 35 0.8× 50 1.3× 35 651
Shani Alston United States 8 145 0.4× 346 1.7× 52 1.1× 58 1.3× 59 1.5× 13 661
Marios Rossides Sweden 13 272 0.7× 289 1.4× 83 1.7× 91 2.1× 64 1.6× 34 576
İsmet Bulut Türkiye 12 169 0.4× 100 0.5× 76 1.6× 57 1.3× 24 0.6× 43 461
Hee‐Young Yoon South Korea 12 290 0.7× 78 0.4× 62 1.3× 38 0.9× 15 0.4× 40 411
Swati Gulati United States 11 322 0.8× 87 0.4× 31 0.6× 49 1.1× 11 0.3× 17 418
Karel Hejduk Czechia 12 324 0.8× 165 0.8× 27 0.6× 31 0.7× 23 0.6× 57 429
Guillaume Beltramo France 10 271 0.7× 35 0.2× 55 1.1× 60 1.4× 16 0.4× 27 450

Countries citing papers authored by Nathan Hambly

Since Specialization
Citations

This map shows the geographic impact of Nathan Hambly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Hambly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Hambly more than expected).

Fields of papers citing papers by Nathan Hambly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Hambly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Hambly. The network helps show where Nathan Hambly may publish in the future.

Co-authorship network of co-authors of Nathan Hambly

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan Hambly. A scholar is included among the top collaborators of Nathan Hambly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan Hambly. Nathan Hambly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Isshiki, Takuma, Megan Vierhout, Asghar Naqvi, et al.. (2025). Upregulation of HSP90α in the lungs and circulation in sarcoidosis. Frontiers in Medicine. 12. 1532437–1532437. 3 indexed citations
2.
Stewart, Duncan, Sanjay S. Mehta, George Chandy, et al.. (2024). Abstract 4141662: Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention with Repeat dosing of eNOS-enhanced EPCs: the SAPPHIRE Trial. Circulation. 150(Suppl_1). 1 indexed citations
3.
Marcoux, Veronica, Prosanta Mondal, Deborah Assayag, et al.. (2023). Treatment of rheumatoid arthritis-associated interstitial lung disease in a multi-center registry cohort. Journal of Thoracic Disease. 15(5). 2517–2527. 6 indexed citations
4.
Sugarman, Jordan, Abdullah Alkhodair, Lisa Mielniczuk, et al.. (2023). Association Between the Pulmonary Artery Pulsatility Index and Prognosis in Pulmonary Arterial Hypertension: A Multicentre Study. CJC Open. 5(7). 545–553. 2 indexed citations
5.
Zheng, Boyang, Nathan Hambly, Kerri A. Johannson, et al.. (2022). Clinical relevance of rheumatoid factor and anti‐citrullinated peptides in fibrotic interstitial lung disease. Respirology. 27(10). 854–862. 2 indexed citations
6.
Khor, Yet H., Mohammed A. Farooqi, Nathan Hambly, et al.. (2022). Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease. CHEST Journal. 163(2). 345–357. 7 indexed citations
7.
Wang, Michael Ke, David Conen, Maura Marcucci, et al.. (2022). Pulmonary hypertension and associated outcomes in noncardiac surgery: A systematic review and meta-analysis. Heart & Lung. 58. 21–27. 1 indexed citations
8.
Assayag, Deborah, Kerri A. Johannson, Charlene D. Fell, et al.. (2021). Treatment Initiation in Patients with Interstitial Lung Disease in Canada. Annals of the American Thoracic Society. 18(10). 1661–1668. 7 indexed citations
9.
Farooqi, Mohammed A., Sachi O’Hoski, Sarah Goodwin, et al.. (2021). Prevalence and prognostic impact of physical frailty in interstitial lung disease: A prospective cohort study. Respirology. 26(7). 683–689. 17 indexed citations
10.
Shapera, Shane, Christopher J. Ryerson, Deborah Assayag, et al.. (2021). Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respiratory Medicine. 191. 106722–106722. 6 indexed citations
11.
Sadatsafavi, Mohsen, Jolene H. Fisher, Julie Morisset, et al.. (2020). Costs of Workplace Productivity Loss in Patients with Connective Tissue Disease–associated Interstitial Lung Disease. Annals of the American Thoracic Society. 17(9). 1077–1084. 5 indexed citations
12.
Wong, Alyson W., Deborah Assayag, Kerri A. Johannson, et al.. (2020). Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax. 76(1). 37–43. 38 indexed citations
13.
Hambly, Nathan, Nader Khalidi, Athol U. Wells, et al.. (2020). Infliximab Therapy in Patients with Refractory Sarcoidosis: A Multicenter Retrospective Review. A1555–A1555. 1 indexed citations
14.
Wong, Alyson W., Lee Fidler, Veronica Marcoux, et al.. (2020). Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. CHEST Journal. 158(3). 1069–1078. 53 indexed citations
15.
Fisher, Jolene H., Martin Kolb, Kerri A. Johannson, et al.. (2019). Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis. BMC Pulmonary Medicine. 19(1). 223–223. 53 indexed citations
16.
Sadatsafavi, Mohsen, Jolene H. Fisher, Julie Morisset, et al.. (2019). Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. CHEST Journal. 156(5). 887–895. 15 indexed citations
17.
Ryerson, Christopher J., Charlene D. Fell, H. Manganas, et al.. (2016). The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. Canadian Respiratory Journal. 2016. 1–7. 34 indexed citations
18.
Hambly, Nathan, et al.. (2016). Pulmonary hypertension: diagnostic approach and optimal management. Canadian Medical Association Journal. 188(11). 804–812. 14 indexed citations
19.
Hambly, Nathan & John Granton. (2015). Riociguat for the treatment of pulmonary hypertension. Expert Review of Respiratory Medicine. 9(6). 679–695. 14 indexed citations
20.
Hambly, Nathan & Parameswaran Nair. (2013). Monoclonal antibodies for the treatment of refractory asthma. Current Opinion in Pulmonary Medicine. 20(1). 87–94. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vladimír Koblížek Breakdown of academic impact, for papers by Bridget F. Collins Breakdown of academic impact, for papers by Rasmus Holmboe Dahl Breakdown of academic impact, for papers by Shani Alston Breakdown of academic impact, for papers by Marios Rossides Breakdown of academic impact, for papers by İsmet Bulut Breakdown of academic impact, for papers by Hee‐Young Yoon Breakdown of academic impact, for papers by Swati Gulati Breakdown of academic impact, for papers by Karel Hejduk Breakdown of academic impact, for papers by Guillaume Beltramo
Rankless by CCL
2026